Stay updated on KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial
Sign up to get notified when there's something new on the KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial page.

Latest updates to the KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2 in the record history. This reflects a version change in the page’s interface rather than substantive trial data.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe sponsor field was updated from 'Karuna Therapeutics' to 'Karuna Therapeutics, Inc., a Bristol Myers Squibb company' to reflect the full corporate affiliation.SummaryDifference0.2%

- Check37 days agoChange DetectedRevision: v3.5.0 added and Revision: v3.4.3 removed in the Record History.SummaryDifference0.1%

- Check44 days agoChange DetectedA new revision entry v3.4.3 was added and the v3.4.2 entry was removed from the page history.SummaryDifference0.1%

- Check73 days agoChange DetectedAdded Revision: v3.4.2 to the history, marking a new release in the study record's version list. Removed the older funding-status notice and Revision: v3.4.1 from the history view.SummaryDifference0.6%

- Check80 days agoChange DetectedAdded a government funding lapse notice and a new page revision tag (Revision: v3.4.1); the previous revision tag (v3.4.0) was removed.SummaryDifference0.6%

Stay in the know with updates to KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial page.